Each patch contains a tiny amount of peanut powder on it and when applied on the skin, the patch becomes a condensation chamber where sweat accumulates. The patch, named viaskin, delivers small amounts of peanut protein through the skin. Dbv technologies is known for developing viaskin technology for administering allergens or antigens to intact skin while avoiding any transfer to the blood. For the study, volunteers with peanut allergies ranging in age from 4 to 25 were given either a highdose patch 250 micrograms of peanut protein, a lowdose patch 100 micrograms, or a placebo. Daily mail, the peanut patch that could save lives.
Followup study of viaskin peanut shows significant. Peanut skin patch may be boon for allergy sufferers, study. Viaskin peanut phase iii trial falls short, still chance. The patch is targeted at children aged 411 who currently follow a peanutfree diet and are at risk of severe, lifethreatening reactions when accidentally exposed. In october 20, the consortium for food allergy research, or cofar. Dbv technologies, the french company that developed the viaskin peanut patch, announced in october that while 35. Epicutaneous immunotherapy for the treatment of peanut. The future of the peanut patch immunotherapy treatment is uncertain after a phase 3 trial failed to meet its main statistical goal.
Over the course of a year, researchers from the consortium of food allergy research tested 74 peanutallergic volunteers, ages 4 through 20, to. The viaskin peanut patch is the latest advancement. Viaskin peanut clinical development has received fast track designation from the us. The treatment, called epicutaneous immunotherapy or epit, was safe and welltolerated, and nearly all participants used the skin patch. Dbv technologies initiates a longterm followup study of. Peanut epicutaneous phase ii immunotherapy clinical trial full. The fda has approved peanut allergen powderdnfp palforzia aimmune for use as oral immunotherapy to mitigate allergic reactions, including anaphylaxis, caused by accidental peanut exposure in patients with a confirmed peanut allergy. The fda has awarded breakthrough therapy designation for peanut allergy treatment to dbv technologies viaskin peanut.
It is the first drug to be approved in the us for this indication. At the same time, another company hopes to offer a peanut patch, called viaskin, which patients will wear for increasing amounts of time to updose and. By how far did the viaskin peanut therapy miss the mark in the trial. Viaskin peanut allergy treatment pipeline dbv technologies. Studies were scarce, and it felt like we had won the lottery. Skin patch to treat peanut allergy shows benefit in. Patch application duration is initially 3 hours and gradually increased to 24 hours over a 21day graduated dosing period. Dbv technologies said that the fda granted its viaskin patch breakthrough therapy designation for the treatment of. The first patch is placed under the supervision of a medical professional, but subsequent patches can be applied at home. Dbv technologies announces initiation of phase iii study. Were hoping that we can get them all to mg of peanut protein or at least a 10 fold increase from their baselinefrom.
Similar to the nicotine patch that reduces tobacco cravings, the peanut patch releases trace amounts of protein found in peanuts. Hugh sampson, director of the jaffe food allergy institute at. Dbv technologies sa is a publicly owned french biopharmaceutical firm headquartered in bagneux, france. Oral immunotherapy and viaskin peanut for peanut allergy icer. Subjects apply placebo viaskin patch daily for a 52week blinded period. Viaskin peanut clinical development has received fast track designation from the us food and drug administration. After 12 months of wearing the patch, they will be challenged, again starting at a very low dose 1 mg with up to mg and then 2000 mg of peanut. The skinbased approach has a major theoretical and now apparent actual advantage over oral immunotherapy in its safety, dr.
According to the cdc there has been a 50% increase in the number of children in. Pepites is expected to enroll approximately 330 patients in about 30 centers across north america canada and the united states, europe, and australia. Viaskin patch, peanut allergy patch, treatment for peanut. Epitope epit in toddlers with peanut allergy epitope epit in toddlers with peanut allergy is a global, phase iii clinical trial assessing the safety and efficacy of viaskin peanut for the treatment of peanutallergic patients one to three years of age. Dbv technologies misses with viaskin peanut allergy patch scrip. Peanut allergy is common, lifethreatening, and without therapeutic options. The viaskin peanut patch offers an alternative to the oral intake method, which has certainly proven to be a more viable method of peanut protein delivery.
Viaskin peanut patch could be the answer to peanut allergies in children jun 24, 20 10. Peanut epicutaneous phase ii immunotherapy clinical trial. Epicutaneous immunotherapy for the treatment of peanut allergy in. Dbv technologies announces fda acceptance of bla filing for viaskin peanut for the treatment of peanut allergy. Each patch was applied for 24 hours on the upper arm. Dbv technologies is focusing on food allergies milk and peanut for which there are currently no effective treatments.
Dbv technologies peanut allergy treatment wins fda. Viaskin peanut patch renews hope for allergic kids. A new peanut allergy vaccine failed in a trial, but the. Viaskin peanut patch is a coin sized selfadhesive disc which is changed daily and applied on either the back for young children or on the upper arm for teens and adults over healthy skin. Peanut allergies are particularly devastating, as even trace amounts of peanuts can cause devastating effects like anaphylactic shock and death. One familys perspective of participating in a peanut. Dbv technologies initiates a longterm followup study of viaskin peanut olfusvipes will be the largest clinical study designed to assess efficacy, safety and longterm tolerance of peanut. The viaskin peanut patch made by the french biotech firm dbv technologies boosted the amount of peanut protein it took to elicit an allergic reaction by at least 10fold, particularly in kids.
Perhaps once the us food and drug administration approves this patch, peanut allergy resistance development via this method will be more widely accepted. A wearable patch that delivers small amounts of peanut protein through the skin shows promise for treating children and young adults with peanut allergy, with greater benefits for younger children, according to oneyear results from an ongoing clinical trial. Hope remains for the viaskin peanut patch allergic living. The viaskin peanut therapy has a robust set of clinical data behind it. Medical daily, viaskin peanut patch could be the answer to peanut allergies in children by justin caba 24 june 20. It marks the first time the fda granted the designation for a food allergy, the francebased company says. Peanut allergy is the most common lifethreatening food allergy, with an overall prevalence of 0. A research note issued by jeffries referred to in fierce pharma stated.
An ongoing trial to further evaluate peanut epit is sponsored by nihs national institute of allergy and infectious diseases niaid and conducted by the niaidfunded consortium of food allergy research cofar. The viaskin peanut patch used for this study is comprised of an. One familys perspective of participating in a peanut patch trial. Viaskin peanut patch is a coin sized selfadhesive disc which is. We evaluated peanut epicutaneous immunotherapy epit by using viaskin. The viaskin peanut patch used for this study is comprised of an epicutaneous delivery system containing a dry deposit of. Each patch was applied for 24 hours on the upper arm for adults age 1855 and adolescents age 1217 or on the back of children age 611. This study evaluates the safety of viaskin peanut 250 mcg in the treatment of peanut allergy in children from 4 to 11 years of age. One year later, my son had his second dbpcfc in december 20. Peanut allergen powder palforzia the medical letter, inc. Viaskin peanut patch could be the answer to peanut. Viaskin peanut dbv technologies is a patch applied daily to the upper back rotating the location. Read about viaskin peanut clinical trial research, an investigational peanut allergy. This latest viaskin peanut skin patch has the potential to change the lives of people all over the.
It hails from dbv technologies, a french biotech company and seeks to replace existing oral immunotherapy options. Dbv technologies is continuing to test the viaskin peanut patch on children with peanut allergies. Fda gives experimental peanut allergy patch special status. Epitope is a twopart, pivotal, doubleblind, placebocontrolled trial currently enrolling patients. Viaskin peanut peanut allergy immunotherapy dbv 712. A skin patch to treat peanut allergies just passed a. Dbv technologies peanut allergy patch missed the markby a whiskerin a phase 3 trial but is still at least 50. After using the viaskin peanut patch for 3 years, 52% of peanutallergic kids aged 411 could tolerate at least milligrams of peanut. We have developed a completely new direct approach to treat a peanut allergy that is safe. Each patch contains 250 micrograms of peanut protein powder, which dissolves into the skin when combined with sweat, gradually training a wearers immune system to handle it. Dbv technologies developed a patented innovative process, the epatch, which is used to. Peanut patch the future of allergy treatment is here today. Safety study of viaskin peanut to treat peanut allergy.
Over 450 patients have been treated in 5 clinical randomized, placebocontrolled, multicenter clinical trials. Researchers with the jaffe food allergy institute at kravis childrens hospital at mount sinai may have a solution. Dbv technologies misses with viaskin peanut allergy patch. New plaster reduces severity of allergic reactions in children by pat hagan 24 june 20. Viaskin peanut allergy patch fast tracked by fda achoo. Viaskin is a small patch which could cure people of peanut allergies over time. Dbv technologies completes enrollment of phase iib vipes. The note also points out that two other drugs similarly missed their.
Viaskin peanut allergy patch fast tracked by fda april, 2015 kevvyg over the last few years there has been a lot of good starts when it comes to novel treatments of allergies and asthma. Subjects will receive either viaskin peanut 250 mcg or a placebo for a period of 6 months, after which all subjects will be receiving the active treatment up to a period of 3 years under active treatment. According to an article in healthday news the viaskin peanut patch, worn for a year by peanutallergic children and adults, appears to educate cells to turn off the allergic reaction, said lead researcher dr. Dbv technologies announces the launch of a proposed global offering of ordinary shares, which may be in the form of american depositary shares, and reports september 30, 2019 cash position. The french firms share price nearly halved on disappointing phase iii data for viaskin while those of its rival, aimmune, shot up, but all hope for the patch product is not yet lost. Will this doctorturnedentrepreneur cure peanut allergies. Peanut allergy drug slated for 2018 debut cnnmoney. So when a few months later, in september of 20, we received a call from new yorks mount sinai hospital, and josh was offered a place in the viaskin peanut patch study, we jumped at the chance. A new peanut allergy vaccine failed in a trial, but the company wants it approved anyway.
652 470 1131 84 746 1078 1248 822 1377 536 1308 862 854 1278 18 593 1340 963 1176 1195 971 876 1316 552 639 522 1433 300 210 35 1001 78 928 530 801 79 972 163 902